New drug aims to starve prostate cancer by blocking testosterone
NCT ID NCT07457164
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a drug called teverelix DP in 40 men with advanced prostate cancer. The drug works by blocking a hormone that tells the body to make testosterone, which can fuel cancer growth. The goal is to see if a specific dosing schedule can safely lower testosterone to very low levels. Results will help decide if a larger phase 3 study should be done.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teverelix DP (a hormone-blocking drug)
What this could lead to
If successful, this could support a larger Phase 3 study and potentially offer a new treatment option for advanced prostate cancer patients at high cardiovascular risk.
What could go wrong
This is a small, early-phase trial with only 40 participants. It may not show the desired testosterone suppression, and safety issues could arise. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.